Thomas M Habermann
Overview
Explore the profile of Thomas M Habermann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
338
Citations
12205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paludo J, Abeykoon J, Perera N, Sarosiek S, Gustine J, Ramirez-Gamero A, et al.
Am J Hematol
. 2025 Mar;
PMID: 40062689
As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However,...
2.
Kleinstern G, Robinson D, Rimsza L, Larson M, King R, Nowakowski G, et al.
Cancer Epidemiol Biomarkers Prev
. 2025 Mar;
PMID: 40047811
Background: Diffuse large B-cell lymphoma (DLBCL) is clinically heterogeneous, and gene expression profiling has identified at least two biologically distinct DLBCL subtypes defined by their cell-of-origin (COO): germinal center B-cell...
3.
Nastoupil L, Andersen C, Ayers A, Wang Y, Habermann T, Chihara D, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39966020
Introduction: Clinical trials provide meaningful data regarding the safety and efficacy of novel therapies but there is often a lag between the time of new drug approval and information on...
4.
Hwang S, Godby R, Negaard B, Mwangi R, Nedved A, Barreto J, et al.
Blood Adv
. 2025 Feb;
9(4):924-932.
PMID: 39964705
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma involving the brain, cerebrospinal fluid, or retina/vitreous without systemic involvement. Induction with high-dose methotrexate (HD-MTX) followed by...
5.
Yamshon S, Koff J, Larson M, Kahl B, Casulo C, Lossos I, et al.
Am J Hematol
. 2025 Feb;
100(4):606-615.
PMID: 39918101
Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but there are limited real-world data. In a multicenter...
6.
Zhu Y, Wong J, Hilal T, Maguire A, Ocal J, Zellner K, et al.
medRxiv
. 2024 Dec;
PMID: 39677423
Primary central nervous system lymphoma (PCNSL) is clinically challenging due to its location and small biopsy size, leading to a lack of comprehensive molecular and biologic description. We previously demonstrated...
7.
Bock A, Wenzl K, Novak J, Stokes M, Hopper M, Krull J, et al.
Hematol Oncol
. 2024 Nov;
43(1):e70006.
PMID: 39612356
Diffuse large B-cell lymphoma (DLBCL) patients that fail to achieve a complete metabolic response with frontline immunochemotherapy have a poor prognosis. Genomic profiling has led to a broader understanding of...
8.
Day J, Larson M, Durani U, Koff J, Wang Y, Habermann T, et al.
Blood Adv
. 2024 Nov;
9(5):1013-1023.
PMID: 39602301
Progression of disease within 24 months of initial immunochemotherapy (POD24) is a negative prognostic factor for patients with follicular lymphoma (FL). There is no standard treatment after POD24. Assembling an...
9.
Atallah-Yunes S, Rees M, Mwangi R, Kuchler R, Nowakowski G, Habermann T, et al.
Am J Hematol
. 2024 Oct;
100(1):158-162.
PMID: 39400430
Differences in characteristics and outcomes between incidental and symptomatic presentations of Large B-Cell Lymphoma.
10.
Atallah-Yunes S, Rees M, Witzig T, Habermann T, Munoz J, Iqbal M, et al.
Haematologica
. 2024 Oct;
110(2):448-456.
PMID: 39385736
Intensified chemoimmunotherapy regimens are often used in young patients with double-hit and triple-hit lymphoma (DHL/ THL) despite no survival benefit compared to R-CHOP. Favorable retrospective reports on the application of...